Daniel Faga - 07 Jan 2026 Form 4 Insider Report for ANAPTYSBIO, INC (ANAB)

Signature
/s/ Eric Loumeau, Attorney-in-Fact
Issuer symbol
ANAB
Transactions as of
07 Jan 2026
Net transactions value
-$638,504
Form type
4
Filing time
09 Jan 2026, 19:12:18 UTC
Previous filing
08 Jan 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Faga Daniel President, CEO, Director C/O ANAPTYSBIO, INC., 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO /s/ Eric Loumeau, Attorney-in-Fact 09 Jan 2026 0001673528

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANAB Common Stock Options Exercise +26,838 +5.7% 493,625 07 Jan 2026 Direct F1
transaction ANAB Common Stock Sale $638,504 -14,281 -2.9% $44.71 479,344 08 Jan 2026 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANAB Restricted Stock Unit Options Exercise $0 -26,838 -25% $0.000000 80,512 07 Jan 2026 Common Stock 26,838 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2 The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3 The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.